Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia
'Epigenetics' refers to changes in gene expression occurring without alterations in DNA sequence. 1 For this paper, the relevant epigenetic events are DNA methylation and, to a less extent, histone modification. 2 DNA methylation typically occurs at the 5 0 -position of cytosine in areas of the genome rich in CpG dinucleotides (CpG islands), results in silencing of gene expression and is fundamental to normal development. DNA methyltransferase 1 (DNMT1) maintains existing methylation patterns following DNA replication, whereas DNMT3A and 3B methylate unmethylated CpGs. In contrast, members of the TET ('10-11 translocation') family of proteins remove methyl groups from CpGs, a process requiring a-ketoglutarate, which is derived from isocitrate in a reaction catalyzed by isocitrate dehydrogenase 1 and 2. Histones undergo many post-translational modifications, including acetylation (which increases gene expression), deacetylation, methylation and demethylation, with different combinations of this 'histone code' leading, via chromatin modification, to activation or repression of gene expression. 1, 2 Relative to their normal counterparts, cancer cells generally exhibit genome-wide hypomethylation and CpG island hypermethylation. 1 The former leads to the genetic instability characteristic of cancer, whereas the latter silences tumor suppressor genes. There is considerable evidence that abnormal methylation has an important role in pathogenesis of acute myeloid leukemia (AML) and myelodysplasia (MDS), the diseases of interest to us here. Circumstantially, mutations in DNMT3a and isocitrate dehydrogenase 1 and 2, and aberrations in the TET 2 gene predicted to disturb its normal function, occur not infrequently in AML and MDS while many commonly observed abnormal fusions of the mixed lineage leukemia gene affect histone methyl transferases presumably activating leukemia promoting genes. More direct evidence comes from findings that AML blasts, particularly those obtained from patients with secondary AML, have DNA methylation patterns distinct from those seen in normal CD34 þ cells 3 and that specific types of AML, for example, those associated with AML1-ETO, CBFb-MYH11, PMLRARa and mutated CEBPA or NPM1 have distinctive methylation patterns. 4 Furthermore, an increase in aberrant DNA methylation was uniformly observed in 184 patients in whom MDS 'progressed' to AML. 5 The latter study did not include a group in whom such progression did not occur and the above data are consistent with epigenetic changes as secondary, rather than primary, events. However, experiments transferring leukemia from mice with reduced DNMT1 activity suggest that constitutive methylation is needed for proper renewal of leukemia stem cells, 6, 7 thus suggesting that epigenetic alterations can be primary events.
Unlike genetic aberrations, epigenetic changes, are reversible, prompting interest in drugs that affect the 'epigenome'. The 'epigenetic drugs' that have found widest use and which we will emphasize are the DNMT inhibitors azacitidine and decitabine. Here we will first discuss their use in (a) lower-risk MDS and (b) higher-risk MDS and AML, recognizing the distinctive therapeutic goals in a and b. We will emphasize comparisons between these drugs and other therapeutic options and discuss the possibility that, although used essentially interchangeably, azacitidine and decitabine may differ qualitatively. Concluding that neither drug is on average satisfactory treatment, particularly for high-risk MDS or AML, we will discuss means to predict response in individual patients. Of particular relevance, we will examine the strength of the evidence that the undoubted clinical activity of DNMT inhibitors and histone decateylase inhibitors results from their undoubted epigenetic effects, as examining this hypothesis seems fundamental to rational development of this class of drugs. Lastly, we will discuss newer approaches to epigenetic therapy, involving use (a) as post remission therapy, particularly after allogeneic hematopoietic cell transplantation (HCT) (b) of different schedules of administration, (c) of pharmacologically improved congeners of decitabine and (d) of combinations with other active agents.
AZACITIDINE AND DECITABINE IN 'LOWER-RISK' MDS
By 'risk' I refer to overall survival (OS), the outcome of most interest to patients. Perhaps the most useful means to assess expected OS in MDS are the revised International Prognostic Scoring System (IPSS-R) based on an exceptionally large database (7012 patients with untreated de novo MDS), 8 the WPSS (World Health Organization -based Prognostic Scoring System), 9 which includes patients with secondary MDS and which addresses changes in prognosis over time, and the MD Anderson prognostic system for lower-risk MDS, 10 which removes some such patients from the lower-risk category. By lower-risk MDS, I mean an expected median OS of X3 years corresponding to the IPSS-R or WPSS groups 'very low', 'low' and 'intermediate', and the MD Anderson category 1. It is generally accepted that the principal therapeutic goal in such patients is to decrease, particularly red blood cell (RBC), transfusions, in the process improving 'quality of life'.
Randomized trials have shown that azacitidine and decitabine are superior to a transfusion-only approach ('best supportive care', BSC) in this regard. RBC transfusion independence for X8 weeks was observed in 45% of 65 RBC transfusion-dependent patients randomized to subcutaneous (s.c.) azacitidine, 11 and B35% of a similar number of transfusion-dependent patients given decitabine 12 versus only a trivial number of BSC patients. Both drugs improve quality of life more than BSC. 12, 13 These results establish azacitidine or decitabine as the preferred options in RBC transfusion-dependent nondeletion 5q low-risk patients who either have failed or are predicted to fail treatment with erythropoietic-stimulating agents, and in patients who are receiving platelet as well as RBC transfusions. It appears that, at least with azacitidine, results similar to those reported from academic centers can be obtained in community settings even in very elderly patients (median age 75). 14 Considerable attention has been devoted to making administration of azacitidine and decitabine as convenient as possible. Thus, there have been suggestions that 5 days of azacitidine are as effective as the initially described 7-day schedule 15 and that s.c. and intravenous schedules are equivalent. Of most interest is an oral azacitidine preparation, 16 which was administered to 41 patients who received a median of six cycles (up to 32) after a single 75 mg m À 2 dose of s.c. drug. Although, at its maximum tolerated dose (480 mg daily Â 7 days every 28 days) exposure to oral azacitidine was less than with s.c. preparation (as was hypomethylation), clinical activity was observed, which likely owed in part to the oral preparation, as responses are unusual after a single dose of s.c. azacitidine. 16 More frequent dosing and/or more extended dosing are planned. Although initial studies with decitabine used a three times intravenous daily schedule, it appears that results are similar with a more convenient once daily 5-day schedule. 17 To date, there have been no randomized trials comparing these various means of administration. More striking is the absence of randomized trials comparing azacitidine with decitabine, or either drug with lenalidomide, which has activity in MDS patients who lack deletion of the long arm of chromosome 5q. 18 Suggestion that the lack of a formal decitabine-azacitidine comparison may be more than an academic issue comes from an analysis, which, using propensity scoring to account for known prognostic factors (such as age, blast percent, IPSS score and karyotype), found superior survival (P ¼ 0.02) in patients aged X65 given azacitidine rather than decitabine; 19 it was not noted whether as seems likely this finding reflected results in the 40% of patients who were higher risk. Such a finding may reflect observed differences in the epigenetic effects of azacitidine and decitabine. 20, 21 Thus, regarding these drugs as interchangeable epigenetic or hypomethylating agents may be an oversimplification.
AZACITIDINE AND DECITABINE IN HIGHER RISK MDS OR AML
The natural history of higher-risk MDS as defined, for example, by IPSS-R or WPSS bears more resemblance to AML than to lower-risk MDS. Indeed European cooperative groups, such as the Medical Research Council and Hemato-Oncologie voor Volwassenen Nederland, and American centers, such as MD Anderson and Fred Hutchinson, now extend eligibility for AML trials to patients with 10-20% blasts, even though these patients are considered to have high-risk MDS rather than AML (the World Health Organization criterion for which is 420% blasts). Perhaps most importantly in both higher-risk MDS and AML, the principal goal of therapy is to improve OS, whereas this aim is less explicit in lower-risk MDS. Hence, I will discuss higher-risk MDS and AML together and focus on OS. As such 'lumping' is not necessarily standard, I will comment on similarities or differences in outcome between higher-risk MDS and AML in various studies (Table 1) .
Randomized trials have reported that either azacitidine or decitabine produce better OS than BSC or low-dose ara-C (LDAC) [23] [24] [25] in patients with either higher-risk MDS or AML 22, 23 or in patients with AML per se 24, 25 (Table 1) . Lubbert et al. 22 noted that OS was shorter in patients with (original) IPSS scores 26 of 'high' than in patients with scores of 'intermediate 2', but it is not clear whether patients with high scores had a blast count 420% (AML), rather than blast counts o20% (MDS) but with 'unfavorable' cytogenetics or lower blood counts, the other components of the original IPSS in any event, the effect of decitabine versus control was the same regardless of the distinction between IPSS high or intermediate 2. Azacitidine reduced the risk of death to the same extent regardless of whether the blast count was 11-20% or 21-30%. 23 An ongoing trial (NCT01074047 at clinicaltrials.gov) is addressing whether the same is true in patients with 430% blasts.
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In neither of the decitabine studies 22, 24 was the difference in OS 'statistically significant', whereas such significance was observed in the azacitidine trials. 23, 25 Rather than merely a function of sample size, the difference between azacitidine and decitabine reflected larger differences between azacitidine and BSC or LDAC than between decitabine and these treatments (Table 1) . Interpretation, however, is complicated because the control group had better OS in the azacitidine than in the decitabine studies. For example, median OS with LDAC was 15-17 months in the former versus 5 months in the latter with this difference greater than that between LDAC and azacitidine in the azacitidine studies. Hence, the patients given azacitidine and those given decitabine may not have been strictly comparable despite similarities in diagnosis. The proportion of patients considered for enrollment but not enrolled was 0% 22 and 23% 24 in the decitabine trials, whereas comparable figures were not provided for the azacitidine trials. 23, 25 The patients in the azacitidine trials also tended to receive more cycles of therapy (Table 1 ) and, as discussed later, the number of cycles administered appears to be important in determining response to epigenetic drugs, although the fewer cycles generally, given the decitabine patients, may have been a result, rather than a cause, of relatively poor outcomes in some patients.
The control group in the azacitidine trials consisted of BSC, LDAC or standard AML induction therapy ('3 þ 7'). While statistically significant differences were seen in favor of azacitidine compared to BSC or LDAC, the number of patients receiving 3 þ 7 was almost certainly too small to detect statistical significance absent very great superiority in favor of azacitidine, although the hazard ratios in favor of azacitidine were less impressive with 3 þ 7 (0.76 in the MDS þ AML trial, 23 0.97 in the AML trial 25 than with BSC (0.58 and 0.48) or LDAC (0.36 and 0.37). The control group in the decitabine trials received BSC in the high-risk MDS study 22 and either BSC or LDAC in the AML study, with 88% of the latter patients receiving LDAC. However, as noted by Ferrara and Musto, 27 the LDAC dose employed (20 mg m À 2 once daily Â 10 days) was lower than that used (20 mg m À 2 daily Â 14 days) in the azacitidine studies, and this may have served to exaggerate the OS differences between decitabine and LDAC. Nonetheless, the complete response (CR) rates (8%) were essentially identical with LDAC in the decitabine and azacitidine studies, 23, 24 although, as noted below, the relation between CR and OS is not necessarily as obvious as once believed. This CR rate was less than that observed (18%) with LDAC (20 mg twice daily Â 10 days) in the MRC's AML 14 trial, eligibility for which was limited to 'unfit' older patients; 28 furthermore, although the Medical Research Council found that half the patients receiving LDAC needed three to four courses to achieve CR the median number of courses received in the decitabine trial was only two. Nonetheless, median OS (5-6 months) seemed approximately the same in the LDAC arm of the decitabine trial and in the LDAC arm of AML 14, recalling the latter was limited to unfit patients, whereas the 23% exclusion rate suggests this was unlikely the case in the decitabine trial. 24 What then are the roles of decitabine and azacitidine in higherrisk MDS and AML? Randomized trials certainly suggest that decitabine at the 15 mg m À 2 tid dose (Table 1) produces longer OS than BSC, and that azacitidine does the same compared with BSC or LDAC in higher-risk MDS (o21% blasts). Azacitidine seems better than BSC or LDAC in patients with AML and 21-30% blasts with extension of these results to patients with 430% blasts awaiting analysis of NCT01074047. Decitabine was not superior to LDAC or BSC in patients with 21-30% blasts but was superior in patients with 430% blasts, 24 although in the absence of a multivariate analysis, it is hard to know whether this reflected blast per cent per se. Comparison of azacitidine and decitabine is complicated by the administration of fewer cycles of decitabine than azacitidine (Table 1) , the limited (azacitidine) or nonexistent (decitabine) use of 3 þ 7 in the respective control groups despite the likelihood that many older patients can likely tolerate this regimen, 29 use of a lower dose of LDAC 28 given for fewer courses in the decitabine trials (Table 1) , and perhaps most importantly by the seeming different nature of the patients in trials of the two agents. Whether either drug is, as often stated, the 'standard of care' for older patients with higher-risk MDS or AML depends on what is meant by standard of care. It seems reasonable to compare new therapies for these diseases to azacitidine or decitabine rather than, as often currently, LDAC. However, it is less clear that for at least some patients the statistically significant improvement in OS with, especially, azacitidine translates into equivalent medical significance. For example, the US Social Security data (http://www.socialsecurity.gov/OACT/population/ longevity.html) indicate that a 65-year-old male will on average live another 18 years. The azacitidine data in Table 1 indicate that a diagnosis of high-risk MDS would result in a loss of 93% of this life expectancy with LDAC versus 89% with azacitidine. Given these data, I would expect some patients would prefer a clinical trial, possibly including azacitidine (or decitabine) to azacitidine alone.
Although there have been no randomized trials, it seems quite plausible that at least in older patients with AML (20-100% blasts) results with azacitidine or decitabine rival, not only those with LDAC but those with 'more intense' therapies. For example, after accounting for prognostic covariates, although not the year of treatment, Quintas-Cardama et al. 30 reported similar OS among 557 patients aged X65 treated with ara-C at doses of 1-2 g m À 2 ± idarubicin or fludarabine±other drugs and 114 patients given decitabine (n ¼ 67) or azacitidine (n ¼ 47) despite higher CR rates with the more intense therapies (Figure 1 ). 30 Although the former drugs are undoubtedly more convenient than the latter, being able to be administered to outpatients, it is not clear that they can be viewed as 'satisfactory'.
It is not clear how many of the patients the Quintas-Cardama et al. study 30 received HCT after the initial therapy. HCT is thought to be the therapy most likely to cure high-risk MDS or AML. Accordingly, a French study examining the effect of azacitidine versus more intense induction chemotherapy on outcome after subsequent HCT in 163 patients is of considerable interest. 31 Ninety-eight patients received induction chemotherapy alone, 48 patients received azacitidine alone and 17 patients received both modalities, in either order. After accounting for age (median 57), the IPSS score (58% intermediate 2 or high, 26 cytogenetics, CR, partial response (PR) or marrow CR (mCR) versus none of these at time of HCT (such responses pre-HCT were seen in 78% with induction chemotherapy, 69% with azacitidine and 53% with both), time from diagnosis to HCT and type of HCT (80% reduced intensity and 54% matched unrelated) OS was similar in the azacitidine and induction chemotherapy groups and worse in the group that received both modalities pre-HCT (Figure 2) , 31 perhaps because of unknown prognostic factors not detectable via multivariate analysis. It seems likely, however, that azacitidine alone will be unable to substitute for HCT if OS is the aim. Thus, although recognizing the risks of selection bias and limiting their multivariate analysis to patients aged 60-70 years with high-risk 12,17 Jabbour et al. 34 noted that chromosome 5 and/or 7 abnormalities and low hemoglobin and platelet levels were independently associated with shorter OS and concluded that the factors for poor outcome with decitabine and with MDS in general were the same. A similar conclusion was reached when testing the value of the IPSS-R in patients treated with Epigenetics in clinical practice EH Estey azacitidine, 35 and heterogeneity in benefit in different subgroups has not been reported when comparing azacitidine with LDAC or BSC, 23, 25 or compare azacitidine/decitabine with more 'intensive' AML regimens. 30 Post-treatment predictors include number of courses administered and response to initial courses. It is often felt that patients should receive at least six cycles of treatment before being declared resistant to azacitidine or decitabine. However, Steensma et al. 17 noted that with the commonly employed 20 mg m À 2 daily Â 5 decitabine schedule 82% of 50 patients who achieved CR, mCR or 'hematologic improvement' (HI) 36 had shown an initial response after two cycles and 90% after three cycles 17 ( Figure 3 ). Likewise, in the Fenaux et al. trial, 23 median time to first response (CR, PR and HI) was two cycles, with 80% of first responses seen by four cycles (Figure 4) . 33 Firty-eight percent of patients who achieve such a first response with azacitidine have been found to proceed to have a better response after a median of another 3.5 cycles. 37 The relation between courses needed to achieve the first or best response and subsequent OS or duration of response seems worthy of further investigation, and given their shorter OS the question of cycles needed to properly evaluate azacitidine or decitabine is considerably more consequential in higher-risk MDS or AML than in lower-risk MDS.
Epigenetics in clinical practice EH Estey de novo MDS or secondary AML, who either received HCT (n ¼ 105; with
A related issue is whether the type of response (CR, CRp PR, mCR, HI, stable disease with mCR and HI defined originally for MDS) 36 affects outcomes presumably of more interest to patients, such as OS or the duration of freedom from transfusions. Proper analysis of the former of course needs a 'landmark' analysis or one incorporating time-dependent covariates to account for the time needed to achieve a given response. A landmark analysis was performed in a French azacitidine compassionate use program for patients with AML by the World Health Organization criteria (420% blasts). The 138 patients, median age 73 years and 50% with 'unfavorable' cytogenetics had a CR rate of 14% but an overall response rate (including CR, CRp, PR and HI) of 54%. 38 CR, PR and mCR on the one hand and HI on the other were each associated with 1 year OS of 55% versus 19% for no response. 38 Using time-dependent covariates, Gore et al. 39 found that even stable, rather than progressive, disease improved OS. Thus, the need for CR to obtain longer OS, seen with traditional anti-AML therapy, 40 is unlikely to apply with azacitidine and decitabine; the same may apply with regard to survival beyond 2 years. 41 Whether these relations would apply in patients who subsequently receive allogeneic HCT, which would often employ reduced intensity conditioning remains to be seen; particularly, given the general reluctance to perform reduced intensity conditioning -HCT in patients with 45% marrow blasts.
BIOLOGIC PREDICTORS OF RESPONSE TO EPIGENETIC THERAPY DNMT3a and TET 2 DNMT and TET2 have important roles in epigenetic pathways. 1, 2 Metzler et al. 42 found that 6/8 patients with DNMT3a mutations (5 single and 3 together with NPM1 mutations) achieved CR with a 10-day schedule of decitabine (described below) versus 13/38 without these mutations. 42 Higher levels of microRNA (miR)-29b, which decrease levels of messenger RNA for the DNMT3a gene, also correlated with better response to decitabine.
42 TET2 mutations did not affect response to this decitabine schedule, although such mutations were associated with a higher CR þ PR þ mCR rate (9/13 vs 23/70) in patients given a standard azacitidine regimen. 43 Decitabine triphosphate Decitabine must be converted to its triphosphate (DAC-TP) to become active. Assays have been developed to measure DAC-TP concentrations in marrow or blood mononuclear cells obtained from patients before and after treatment with decitabine. Two reports, one in seven, and the other in three patients, have found higher DAC-TP levels in responders. 44, 45 DNA methylation Despite their description as 'hypomethylating agents', it has proven difficult to consistently demonstrate correlations between response to azacitidine or decitabine and pre-or post-treatment DNA methylation status. found no correlation between their pre-treatment methylation status and response to decitabine on the 15 m À 2 TID Â 3 days Q 4-week schedule. 22 However, methylation averaged over multiple time points after therapy decreased more in patients given decitabine than BSC, and, in decitabine-treated patients, more with CR or PR than with HI, and more with HI than with stable or progressive disease. Examining phosphoinositide-phospholipase b1C (PI-PLb1C), a gene thought important in MDS evolution to AML, but this not examined by Shen et al., 46 Follo et al. 47 found a decrease in methylation and/or increase in PI-PL C b 1 expression in 10/10 high-risk MDS patients achieving CR or HI with azacitidine but in 0/8 nonresponders. Ettou et al. 48 found that low expression of FAS (a pro-apoptotic protein) at diagnosis, reflecting hypermethylation of the Fas gene promoter, correlated with response rate (CR þ PR þ HI) to azacitidine independently of age, IPSS, or prior therapy, although the derivation of the cutpoint used to define low Fas expression is not obvious, nor did Fas expression Epigenetics in clinical practice EH Estey correlate with OS after azacitidine. An increase in Fas expression after azacitidine correlated with response. 48 However, in patients given azacitidine þ the histone deaetylase inhibitor etinostat and sequentially analyzing, during cycle 1, four presumed tumor suppressor genes, not including Fas but including two genes that were studied by Shen et al., 46 Fandy et al. 49 could find no relation between clinical response, baseline methylation, or changes in methylation or gene expression in any of the four genes in either the bulk or the CD34 þ population despite induction of histone acetylation. Klco et al. 50 used a novel means to expand primary AML cells in culture and studied a vast number of genes 3 days after treatment with decitabine in clinically relevant concentrations, noting that longer exposure, as often done, results in differentiation and resultant changes in methylation and expression independent of decitabine. They found only limited correlation between decitabine-induced changes in methylation and gene expression. Rather than affecting a specific group of genes, in particular those most commonly monitored after decitabine or azacitidine treatment, decitabine affected a range of genes, typically those most methylated pre-treatment. The authors conclude that 'the mechanism of action of decitabine is more complex than previously recognized'. The implications for rational development of epigenetic drugs are obvious.
NEWER DIRECTIONS: EXTENDED DURATION DECITABINE AND AZACITIDINE
Although decitabine has generally been given at 20 mg m À 2 daily for 5 days, Blum et al. 51 extended the duration to 10 days in 53 patients with untreated AML, median age 74 years. The CR rate was 47% and adding in mCRs gave a response rate of 64%. Also, using a 10-day schedule, Ritchie et al. 52 reported a CR rate of 40%. Although median OS was only about 1 year in the Blum et al. study 51 and 10 months in the Ritchie et al. study, 52 these results seem superior to those obtained in the Kantarjian et al. 24 randomized trial using 20 mg m À 2 daily Â 5. All these patients are typically described as having 'poor prognostic features'. Nonetheless, it is not implausible that various biases might have been operating in each study, emphasizing the need for a randomized trial comparing the 5-and 10-day schedules. The same applies to reports in Prebet et al. 53 that a 10-day schedule of azacitidine is superior to the conventional 7-day schedule.
NEWER DIRECTIONS-'SECOND-GENERATION' HYPOMETHYLATING AGENTS SGI-110 is a dinucleotide of decitabine and deoxyguanosine that is given s.c. It was administered on either a weekly or daily Â 5 schedule to 78 patients (64 AML and 14 MDS). 54 Assuming a relation between hypomethylation and clinical outcome, the biologically effective dose was declared to be 60 mg m À 2 daily Â 5, at which hypomethylation reached a plateau of 25%, which compared 'favorably' with that seen with 20 mg m À 2 decitabine given intravenous. All responses (2CR, 1 CRp, 1 CRi in AML, 1 mCR and 1 HI in MDS patients previously given azacitidine), occurred in patients with 410% hypomethylation. The s.c. exposure resulted in a prolonged half-life compared with that seen with intravenous decitabine (2.4 vs 0.6 h).
NEWER DIRECTIONS: COMBINATION THERAPY
Combinations of epigenetic drugs The possibility of additive or synergistic effects resulting from combined epigenetic therapy (see, for example, Follo et al. 55 ) has motivated numerous studies examining this possibility. These generally have involved addition of histone deacetylase inhibitors to azacitidine or decitabine. The investigated histone deacetylase inhibitor included phenylbutyrate, 56 valproic acid ( ± ATRA, 57, 58 MGCD0103 (Garcia-Manero et al. 59 ) and etinostat. 60 With the exception of the last study, these have been single-arm trials and the number of patients treated has been too small, and their prognoses too heterogeneous to allow a meaningful comparison with single-agent azacitidine or decitabine. Prebet et al. 60 randomized 150 patients (65% MDS and 35% AML) to 10 days of azacitidine ±etinostat. Although the 10-day schedule seemed superior to a 7-day schedule, addition of etinostat had no effect on response rate or OS (18 months without and 13 months with etinostat). Although one group found a relation between changes in p15 methylation and response, 56 others also examining the p15 gene did not. 57, 58 Azacitidine þ lenalidomide Sekeres et al. 61 gave 36 patients, median age 68 years, with higher-risk MDS (87% with original IPSS intermediate 2 or high, the remainder with 5-9% blasts, none with AML as defined by the World Health Organization) azacitidine 75 mg m À 2 daily days 1-5 þ lenalidomide 10 mg daily days 1-10 repeated every 28 days. 61 The median number of cycles was five contrasted with nine in the Fenaux et al. study, 23 which produced similar results in patients with high-risk MDS and those with 20-30% blast AML. 23, 25 Although Sekeres et al. 61 observed a CR rate of 44% versus 17% in the Fenaux et al. study, 23 median OS was less (13 vs 22 months), again pointing out the possible disconnect between CR and OS, and stressing the need for the planned North American randomized trial comparing azcitidine ± lenalidomide in MDS/ Pollyea et al. 62 gave 42 patients aged X60 years (median 74 years) with untreated AML azacitidine 75 mg m À 2 daily Â 7 followed on day 8 by escalating doses of lenalidomide (5, 10, 25, 50 mg) Â 21 days with cycles repeated every 42 days. 62 The 50-mg dose was considered the maximum tolerated dose and patients received a median of five cycles. The CR rate was 19% and the CR þ CRi þ PR rate 41%. Although OS did not differ according to CR þ CRi versuss PR, and was not worse in patients with 'unfavorable' prognosis according to the European Leukemia Net Classification, 63 the median OS was only 20 weeks versus 40 weeks in the French compassionate azacitidine program for 138 patients (median age 73 years) with untreated AML. 38 It is similarly unclear whether the 1 CR, 1 PR and 3 CRi seen in 20 patients with high-risk MDS or AML together with del5q and generally a complex karyotype, who received azacitidine 75 mg m À 2 daily Â 5 days and lenalidomide in escalating doses (10-25 mg daily) days 6-19 (Platzbecker et al. 64 ) is superior to what might have occurred with lenalidomide 10 mg daily alone, given a report of a response rate of 27% in 47 patients with high-risk MDS in such patients Ades et al.
65
Decitabine þ bortezomib The association between higher levels of miR-29b and response to a 10-day course of decitabine, 51 and the ability of bortezomib to induce miR-29b expression motivated combination of these drugs in AML. 66 Although the number of patients treated was small (10 untreated and 9 relapsed/refractory), there was a trend to increased miR-29b expression post treatment. Neurotoxicity due to bortezomib occurred with repetitive cycles. A phase 2 trial randomizing patients to decitabine ± bortezomib is underway.
Combinations with AML-type therapy This is likely to be an area of increasing interest. To date, most of the trials have been small, intended to establish 'feasibility' with limited comparison with other therapy. I will discuss two studies. Garcia-Manero et al. 67 administered vorinostat 500 mg tid for 3 days and then gave idarubicin þ ara-C at standard MD Anderson doses (idarubicin + ara-C: 12 mg m À 1 daily days
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Epigenetics in clinical practice EH Estey 4-6, 1.5 g m À 2 daily Â 3-4 days by continuous infusion). Seventyfive newly diagnosed patients aged o65 years were treated and CR rate was 76% (85% CR þ CRp) and median OS was 82 weeks. 67 As part of an effort to identify the 'experimental' arm for the next US intergroup phase 3 trial in patients aged o65 years, who do not have core-binding factor or FLT3ITD þ AML, a multivariate analysis, accounting for age, cytogenetics and de novo versus secondary AML, was undertaken and identified IA þ vorinostat as associated with a higher CR rate than IA without vorinostat, as well as several other single arm regimens (Othus, personal communication) . Accordingly, IA þ vorinostat will be the experimental induction arm to be compared with IA and 3 þ 7 in this phase 3 trial. Scandura et al. 68 gave decitabine for varying times immediately before standard 3 þ 7 therapy and reported a CR rate of 25/30 (with 8 of the CRs occurring with the patients' next therapy) in a population in which 83% had at least one 'high-risk' feature; median OS had yet to be reached (lower bound of 95% confidence interval, 15 months).
NEWER DIRECTIONS-USE IN PATIENTS IN REMISSION OR AFTER HCT
The discussion so far has focused on patients with 'active disease'. However, it is quite plausible that agents that are relatively ineffective in this setting will be more active in patients with less obvious disease. With this in mind, the US Alliance (formerly CALGB) gave decitabine (20 mg m À 2 daily Â 4-5 days every 6 weeks for a planned eight cycles) to AML patients who had completed post remission therapy (three cycles of 'high-dose' ara-C or an autologous transplant) and were within 90 days of their last therapy. One hundred and thirty four out of 412 CR patients received decitabine, with 75% of the 134 receiving at least 4 cycles. Although it is not clear whether the 134 were representative of the 412, OS and disease-free survival from registration were similar to that observed in a previous Alliance study in which patients, given identical induction and post-remission therapy, received no further therapy or interleukin-2 (Blum et al. 69 ). Boumber et al. randomized 45 patients (35 in first, 10 in second and CR or CRp) between decitabine at 20 mg m À 2 daily Â 5 every 4-8 weeks (median number of cycles ¼ 4.5) and either observation, low-dose ara-C, or 'intensive' chemotherapy. 70 Multivariate analysis found that presence of minimal residual disease at time of randomization reduced OS and disease-free survival, whereas treatment with decitabine had no effect. Although the number of patients randomized may have been too small to detect any but very powerful decitabine effects, it appears fair to say that, as often the case, disease characteristics (here minimal residual disease) dominate treatment as predictors of outcome.
There are considerable pre-clinical data, suggesting that epigenetic drugs, particularly azacitidine, might be effective in the post-HCT setting due to its ability to (a) augment graft versus AML effect by increasing the immunogenicity of AML blasts 71 or demethylating KIR regions on donor natural killer cells, 72 and (b) suppress acute graft versus host disease by increasing numbers of regulatory T cells 73, 74 and reducing production of proinflammatory cytokines. 75 Schroeder et al. 76 gave azacitidine (100 mg m À 2 daily Â 5 days every 28 days) with donor lymphocyte infusions on day 6 of cycles 2, 4 and 6 as first salvage therapy to 30 patients with relapsed (median 34% blasts) AML (n ¼ 28) or MDS after HCT (reduced intensity in 26 patients). CR rate was 23% and CR þ PR rate was 30% with median time to best response three cycles and median OS 117 days. 77 The authors noted that this outcome was not obviously different than what might be expected in similar patients. However, they also commented that the rates of acute graft versus host disease and of grade 2-4 acute graft versus host disease (37% and 17%) were lower than typically reported, perhaps reflecting an increase in regulatory T cells, particularly in patients with early relapse.
Perhaps of more interest are studies in patients with less apparent disease. de Lima et al. 77 administered four cycles of s.c. azacitidine at varying doses Â 5 days starting on day 43 after reduced intensity HCT, provided the patient was in CR on day 30. Thirty patients had active AML or high-risk MDS at the time of HCT and 15 were in CR1, but at high risk of relapse. The 'optimal' dose was 32 mg m À 2 given for four cycles with thrombopenia dose limiting. With median 20.5 months follow-up, 1-year event-free survival (58%) and OS (77%) were felt to warrant a currently ongoing randomized trial. A better indicator of the potential efficacy of this approach comes from a study of Platzbecker et al.
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They had previously established that a loss of CD34 þ donor chimerism below 80% after HCT was a very strong predictor of relapse after a median of 2 months, prompting the administration of four cycles of azacitidine 75 mg m À 2 daily Â 7 every 4 weeks to 20 patients with such loss of donor chimerism. Ten patients had an increase in donor chimerism to 480%; four of these remain in remission at median of 11 months and the remaining six relapsed at a median of 12 months. Three out of ten patients who did not achieve an increase in donor chimerism to 480% remain in remission at a median of 10 months, with the remaining seven relapsing but at a median of only 6 months. Thus, it seems fair to infer that azacitidine delayed relapse compared with historical data with perhaps more delay in patients in whom donor chimerism increased 480%.
SUMMARY
There is no doubt that azacitidine and decitabine, the two most prominent epigenetic drugs, have altered the therapeutic landscape in MDS and AML. However, as often the case, the very success of a therapy raises further questions (Table 2) . Beginning with perhaps the most mundane, are decitabine and azacitidine Table 2 . Questions possibly worthy of further exploration 19, 21 In lower-risk MDS In higher-risk MDS or AML General questions
SPOTLIGHT
Are 5 and 7 day schedules of azacitidine equivalent?
Are 10 days of decitabine superior to 5, or 10 days of azacitidine superior to 7?
Are decitabine and azacitidine interchangeable?
What is role of oral azacitidine?
What is role for combination with other 'epigenetic drugs' , lenalidomide, bortezomib or more traditional AML therapy?
Can clinical marker(s) be found to permit earlier discontinuation in patients unlikely to respond to continued therapy? Might epigenetic drugs be more relatively effective in CR post HCT than in active disease?
How much of the activity of hypomethylating drugs results from hypomethylation?
Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplasia; CR, complete response; HCT, hematopoietic cell transplant.
Epigenetics in clinical practice
19 Some patients receive the former, others the latter, but the reasons for this choice do not appear totally based on comparative data. In lower-risk MDS patients, the role of oral azacitidine awaits definition and there is uncertainty as to the merits of a 5 day, permitting weekends off, versus a 7-day schedule of the parenteral drug, again reflecting a dearth of comparative data. Given the short OS of patients with higher-risk MDS or AML questions here, such as the role of 10 days (or perhaps longer) of administration and of combinations with other active drugs, are in need of quicker resolution. Although understandably enough, emphasis to date has been on patients with frank MDS or AML, are there situations that would inherently lend themselves to more successful use of epigenetic therapies, for example, in remission after HCT? Identification of clinical indicators of early response would spare patients from continuing therapy with only a small chance of success. Best would be biologic markers to guide therapy. Currently, there appears to be uncertainty as to how much of the activity of hypomethylating agents owes to hypomethylation. [49] [50] The view that they merely allow re-expression of tumor suppressor genes may be an oversimplification. Although a complex task, understanding how these drugs work appears fundamental to their rational development.
